The startup focuses on glioblastoma tumors with CAR-T therapy.
CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted.
The scientists at McMaster University and the University of Toronto have developed a CAR-T therapy for the aggressive brain cancer glioblastoma. It aided in reducing the burden of the tumour and enhanced survival in mouse models as published in the journal Cell Stem Cell.
The researchers launched a startup known as Empirica Therapeutics, which targets to bring the...
